News Image

Will NOVO-NORDISK A/S-SPONS ADR breakout?

By Mill Chart

Last update: Nov 30, 2023

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) has been identified as a Technical Breakout Setup Pattern by our stock screener. This pattern typically occurs when a stock takes a pause after a significant rise, indicating the possibility of a continuation in the trend. While it's impossible to predict with certainty, it might be beneficial to monitor NYSE:NVO.

NVO Daily chart on 2023-11-30

Insights from Technical Analysis

Every day, ChartMill assigns a Technical Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various technical indicators and properties.

Overall NVO gets a technical rating of 10 out of 10. This is due to a consistent performance in both the short and longer term time frames. Also compared to the overall market, NVO is showing a nice and steady performance.

  • The long and short term trends are both positive. This is looking good!
  • Looking at the yearly performance, NVO did better than 95% of all other stocks. We also observe that the gains produced by NVO over the past year are nicely spread over this period.
  • NVO is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 93% of 205 stocks in the same industry.
  • NVO is currently trading near its 52 week high, which is a good sign. The S&P500 Index however is also trading near new highs, which makes the performance in line with the market.
  • In the last month NVO has a been trading in the 96.00 - 105.69 range, which is quite wide. It is currently trading in the middle of this range where prices have been consolidating recently, this may present a good entry opportunity, but some resistance may be present above.

For an up to date full technical analysis you can check the technical report of NVO

How do we evaluate the setup for NYSE:NVO?

ChartMill takes into account not only the Technical Rating but also assigns a Setup Rating to each stock. This rating, on a scale of 0 to 10, reflects the degree of consolidation observed based on short-term technical indicators. Currently, NYSE:NVO exhibits a 8 setup rating, indicating its consolidation status in recent days and weeks.

NVO has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is very little resistance above the current price. There is a support zone below the current price at 97.52, a Stop Loss order could be placed below this zone.

Trading setups like NYSE:NVO

One strategy to consider is waiting for the actual breakout to occur, where the stock breaks out above the current consolidation zone. Traders can then enter a buy position, anticipating further upward momentum. As a risk management measure, it is advisable to set a stop loss order below the consolidation zone.

Please note that this article should not be construed as trading advice. The information provided is solely based on automated technical analysis and serves to highlight technical observations. It is important to conduct your own analysis and make trading decisions based on your own judgment and responsibility.

Our Breakout screener lists more breakout setups and is updated daily.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (4/30/2024, 5:16:08 PM)

After market: 128.5 +0.19 (+0.15%)

128.31

+1.43 (+1.13%)

NVO News

News Image2 hours ago - InvestorPlace3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.

The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18.

News Image11 hours ago - Investor's Business DailyEli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat

Overall revenue fell short in Q1. Lilly stock is set to cross a key level.

News Image14 hours ago - ChartmillAnalyzing NYSE:NVO's Dividend Potential.

Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) provides a good dividend, while having solid fundamentals.

News Imagea day ago - The Motley FoolBillionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks

The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.

News Image2 days ago - Yahoo FinanceA Fed meeting, jobs report, and more Big Tech earnings: What to know this week

After a bounceback week for stocks, a Fed meeting, jobs report, and a busy week of corporate earnings are set to greet investors.

News Image2 days ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image3 days ago - The Motley FoolForget Nvidia, These Unstoppable Stocks Are Better Buys

These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.

News Image3 days ago - The Motley Fool1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.

News Image4 days ago - Market News VideoInteresting NVO Put And Call Options For June 7th
News Image5 days ago - ChartmillIs NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?

Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.

News Image6 days ago - InvestorPlace3 Biotech Stocks With Skyrocketing Potential: April 2024

These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.

News Image6 days ago - The Motley FoolMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly recently announced news that could solve a big problem.

NVO Links
Follow us for more